Interleukin-6 (IL-6), the major proinflammatory cytokine, has been described to be associated with the hypertensive and atherosclerotic states. We aimed to explore whether the concentration of circulating IL-6 and adhesion molecules could be modified by decreasing blood pressure in hypertensive subjects. A total of 30 subjects (18 men), aged 34-48 years, were enrolled in this study, 17 hypertensive never-treated patients (HTA) and 13 normotensive subjects (C). HTA subjects were treated with irbesartan, 150-300 mg/day for 3 months, and serum IL-6, vascular cell adhesion molecule-1, intercellular adhesion molecule-1, sP-selectin, sE-selectin and monocyte chemoattractant protein-1 were measured at 0 and 12 weeks. The two study groups were similar in age, body mass index (BMI) and gender.
Introduction
Atherosclerosis is increasingly recognised as an inflammatory disease. Interleukin-6 (IL-6) is a multifunctional cytokine produced by many different cell types, including immune cells, endothelial cells, fibroblasts, myocytes and adipocytes. 1 IL-6 is one of the major proinflammatory cytokines, having a pivotal role in the inflammatory process involved in atherosclerotic disease. Raised IL-6 levels and leucocyte adhesiveness have been found to be associated with increased blood pressure, linking hypertension to a proinflammatory state. 2 Adhesion molecules like soluble E-selectin and P-selectin have also been reported to be increased in patients with essential hypertension. 3, 4 Antihypertensive drugs show different properties not directly related to the primary effect. 5 A type 1 specific angiotensin (AT1) receptor blocker like valsartan led to an improvement of inflammatory vascular injury. 6 Losartan also displayed antioxidant properties leading to a decreased oxidation rate of low-density lipoprotein. 7 We aimed to explore whether the concentration of the inflammatory markers IL-6, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), sP-selectin, sE-selectin and monocyte chemoattractant protein-1 (MCP-1) could be modified by decreasing blood pressure in hypertensive patients with irbesartan.
Patients and methods
A total of 30 patients were enrolled in this study. All subjects were of Caucasian origin and reported that their body weight had been stable for at least 3 months before the study. None of the subjects was taking any medication or had any evidence of metabolic disease other than obesity. Thus, we designed a protocol to avoid the influence of any risk factor other than hypertension. Inclusion criteria for this group were: (1) absence of clinical cardiovascular disease; (2) absence of any systemic disease; (3) absence of any infections in the previous month; (4) normal serum cholesterol levels (defined as cholesterol o6.5 mmol/l); (4) no smoking; (5) no diabetes or fasting glucose o126 mg/dl.
The patients were subdivided into two groups. Group 1 included 17 patients with essential hypertension (recently diagnosed essential hypertension with systolic blood pressure (SBP) X140 mmHg, diastolic blood pressure (DBP) X90 mmHg), who had never received antihypertensive drugs; and group 2 included 13 normotensive patients.
Resting blood pressure was measured after subjects had been in a sitting position for a minimum of 15 min using a mercury sphygmomanometer, and was read three times on the right arm by the same investigator. The mean of the three measurements was used for this study. All women had regular menstrual cycles and were studied in the follicular phase of the menstrual cycle.
Informed written consent was obtained after the purpose, nature and potential risks of the study were explained to the subjects. The experimental protocol was approved by the local scientific committee.
Diagnosis of essential hypertension was established by absence of clinical evidence of secondary hypertension and by normal serum electrolytes, creatinine, urinalysis, abdominal echography, and, when indicated, renal scintiscan or computed abdominal tomography. Patients received irbesartan, 150 mg per day, which was increased to 300 mg per day if blood pressure persisted at levels higher than 140/90 mmHg after the first month.
The study strength was calculated from a previous study seeking the relationship of IL-6 with blood pressure. 2 Assuming an alpha risk of 0.05, a beta risk of 0.10 and a bilateral test, 13 subjects were needed to detect a difference greater than 0.6 (the standard deviation of IL-6 in control normotensive subjects). A greater number of patients were included to further decrease the alpha and beta risks.
The study spanned 12 weeks with serum samples collected at 0 and 12 weeks. One patient renounced to follow up.
Anthropometric measurements
BMI was calculated as weight (in kilograms) divided by height (in metres) squared. The subject's waist was measured with a soft tape midway between the lowest rib and the iliac crest. The hip circumference was measured at the widest part of the gluteal region. The waist-to-hip ratio (WHR) was then calculated.
Analytical methods
Blood samples were drawn at 08:00-09:00, after an overnight fast, with subjects in seated position, from the antecubital vein, and were then centrifuged at 3000 r.p.m. Serum samples were stored at À701C until required for assays.
The serum glucose concentration was measured in duplicate by the glucose oxidase method. Total serum cholesterol was measured through the reaction of cholesterol esterase/cholesterol oxidase/ peroxidase. Total serum triglycerides were measured through the reaction of glycerol-phosphateoxidase and peroxidase. Serum HDL cholesterol levels were assessed by enzymatic methods (Boehringer, Mannheim, Germany), and LDL cholesterol levels were assessed by the method of Friedewald et al.
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Serum IL-6 was measured using a commercial immunoassay (MEDGENIX IL-6 EASIAt, BioSource Europe S.A., Zoning Industriel B-6220, Fleunes, Belgium), with coefficients of variation lower than 6%. VCAM-1, ICAM-1, sP-selectin and sE-selectin were measured by enzyme-linked immunosorbent assay (ELISA) with coefficients of variation of 3, 8, 6 and 5%, respectively (Bender-MedSystem, Vienna, Austria). Assays for MCP-1 were performed with the use of commercially available ELISA kits (R&D Systems, Minneapolis, MN, USA) with coefficient of variation lower than 6%. Fibrinogen was measured by nephelometry with ACLt analyst.
Statistical analysis
Descriptive results of continuous variables are expressed as mean7standard deviation (s.d.). Before statistical analysis, normal distribution and homogeneity of the variances were tested. Parameters that did not fulfil these tests (IL-6, serum triglycerides, fibrinogen) were log transformed. Comparisons were performed using paired Student's t-test. The relations between variables were analysed by simple correlation (Pearson's and Spearman's tests) and multiple regression in a stepwise manner. Levels of statistical significance were set at Po0.05.
Results
Anthropometric and biochemical characteristics of the subjects at time of entry into the study are shown in Table 1 . We included 16 young hypertensive patients (10 men) and 13 control subjects (8 men) who were comparable in age, BMI, WHR and plasma lipids concentration. When all subjects were considered as a whole (Table 2) , baseline IL-6 concentration was significantly associated with SBP (r ¼ 0.41; P ¼ 0.03), fibrinogen (r ¼ 0.53; P ¼ 0.005), triglycerides (r ¼ 0.50; P ¼ 0.009) and BMI (r ¼ 0.53; P ¼ 0.005).
VCAM-1, ICAM-1, selectin-E, selectin-P and MCP-1 showed no differences between the two groups. Despite the fact that IL-6 tended to be higher in hypertensive than in control subjects, the differences did not reach statistical significance. However, when the concentration of IL-6 was evaluated according to sex, we found that hypertensive women showed significantly increased IL-6 levels compared to control subjects (P ¼ 0.04).
Irbesartan treatment decreased blood pressure significantly (SBP, from 151714 to 13078 mmHg; DBP, from 9676 to 81.875 mmHg) ( Table 3) . No significant changes in BMI, WHR, plasma lipids or serum fibrinogen were observed after treatment. Irbesartan led to significantly decreased circulating IL-6 levels (P ¼ 0.02) reaching similar levels to those present in the control, normotensive group. The reduction in the IL-6 levels was similar to the reduction in arterial blood pressure (Figure 1) .
Irbesartan produced no change in baseline soluble VCAM-1, ICAM-1, sE-selectin, sP-selectin and MCP-1, which were not raised at baseline in our HTA patients. No episode of major side effect was registered.
Discussion
We have previously described that blood pressure levels have been directly associated with circulating IL-6 concentrations in healthy subjects, 2 and a significant graded relationship between blood pressure and levels of IL-6 and ICAM-1 has been observed in apparently healthy men. 9, 10 These conclusions are coincident with our results, since in our study we have found a significant relationship between SBP and circulating IL-6 concentration in a sample of young hypertensive subjects.
On the other hand, this is the first study to explore the effect of lowering blood pressure with irbesartan on circulating IL-6 levels in young hypertensive patients. We have found that irbesartan led to decreased IL-6 in parallel to lowering of blood pressure in a relatively short time period. To our knowledge, only few papers (summarised in Table 4) have examined the anti-inflammatory effects of the angiotensin receptors blockers. We would like to emphasise that none of these studies enrolled recently diagnosed hypertensive patients, and all the studies were performed in patients with associated complications.
Experimental data in animal models have shown an inhibition of the inflammatory component of the atherosclerotic lesions after treatment with irbesartan 11 and valsartan. 6 In addition to blood pressure, IL-6 can contribute to atherogenesis in several other ways, such as its influence on adhesion molecules, by increasing endothelial permeability, promoting vascular smooth muscle cell proliferation or inducing lipid abnormalities.
12 IL-6 can also lead to increased collagen, 13 and raised fibrinogen synthesis.
14 In our study, serum levels of VCAM-1, ICAM-1, sE-selectin, sP-selectin and MCP-1 did not change significantly after therapy with irbesartan. Although irbesartan has been known to decrease serum levels of VCAM-1 15 and MCP-1 16, 17 in experimental models, Prasad et al 18 did not find significant changes in VCAM-1 and ICAM-1 after therapy with losartan in 31 coronary heart disease patients. Recently, Fliser et al 19 did not find changes in ICAM-1 after therapy with Olmesartan in 199 patients with essential hypertension and diagnosed atherosclerotic disease. It is plausible that a longer treatment period or treatment of higher risk patients could influence additional markers.
It is important to remark that IL-6 can induce angiotensinogen expression, 20 leading to a higher concentration of angiotensin II. Many of the proatherosclerotic effects of angiotensin II are mediated by binding of the peptide to the AT1 receptor. 21 Angiotensin II has been shown to facilitate the recruitment of monocytes into the vessel wall by stimulating the production of MCP-1 and VCAM-1 in in vitro cultures of smooth muscle cells and endothelial cells. 21, 22 Indeed, in vitro data have shown that the oxidant stress triggered by angiotensin II may contribute to enhanced oxidation of LDL and degradation of nitric oxide, and stimulate the expression of ICAM-1 23 and IL-6. 24 Interestingly, IL-6 induces oxidative stress and endothelial dysfunction by overexpression of angiotensin II type 1 receptor. 25 Although most of the beneficial effects provided by AT1 blockers appear to be related to blockade of AT1 receptor, 25 some positive effects of these drugs could be due to the stimulation of AT2 receptors. This stimulation leads to improvement of the inflammatory vascular injury, antagonising the effects of angiotensin II on arterial hypertrophy and fibrosis, and inhibiting IL-6 expression. 6 A limitation of our study is the relatively small sample size. Although the results suggest an antiinflammatory effect of irbesartan in relation with decreased arterial blood pressure, further studies will be needed in a larger number of patients to confirm these findings. It also remains unclear whether lowering of blood pressure by other means contributes to the reduction in IL-6.
In conclusion, irbesartan seems to act as an antiinflammatory molecule as suggested by the lowering of circulating IL-6 levels after 3 months of therapy. It is possible that a longer treatment period, or using higher risk patients, could influence additional markers. Further studies are needed to confirm these observations.
